Garry Nicholson

Garry Allen Nicholson currently works at Abdera Therapeutics, Inc., as Chairman, Avenzo Therapeutics, Inc., as Director, and TScan Therapeutics, Inc., as Independent Director from 2024.
Mr. Nicholson also formerly worked at XTuit Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2015 to 2016, G1 Therapeutics, Inc., as Chairman from 2019 to 2024, Day One Biopharmaceuticals, Inc., as Chairman from 2022 to 2026, Five Prime Therapeutics, Inc., as Independent Director from 2017 to 2021, Tesaro, Inc., as Director, Personal Genome Diagnostics, Inc., as Independent Director, Turning Point Therapeutics, Inc., as Independent Director from 2021 to 2022, SQZ Biotechnologies Co., as Director, The Pfizer Foundation, Inc., as Director, NextCure, Inc., as Independent Director from 2020 to 2023, Tmunity Therapeutics, Inc., as Director, and Pfizer Inc., as President-Pfizer Oncology from 2008 to 2015.
Mr. Nicholson received his undergraduate degree from The University of North Carolina at Chapel Hill and Masters Business Admin degree from the University of South Carolina.